CTBO - Cantabio Pharmaceuticals, Inc.
Cantabio Pharmaceuticals, Inc.
2225 East Bayshore Road
Suite 200
Palo Alto, CA 94303
United States
844-200-2826
https://www.cantabio.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno:
Figure dirigenziali chiave
| Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
|---|---|---|---|---|
| Dr. Gergely Toth | Founder, CEO, Pres & Director | 157k | N/D | 1974 |
| Dr. Thomas Roger Sawyer M.B.A., Ph.D. | CFO & Director | 109k | N/D | 1970 |
| Dr. Balász Herberth | Head of Cell Biology & In Vitro Pharmacology | N/D | N/D | N/D |
Descrizione
Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson's disease (PD), Alzheimer's disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.
Governance aziendale
L'ISS Governance QualityScore di Cantabio Pharmaceuticals, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.
